Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired, immune-mediated disorder of the peripheral nervous system. Protheragen leverages cutting-edge insights into the pathogenesis and genetic drivers of CIDP to pioneer targeted therapies and precision animal models, accelerating preclinical drug development. Our goal is to offer reliable and end-to-end support to streamline your therapeutic development journey.
Overview of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired, immune-mediated disorder of the peripheral nervous system characterized by progressive or relapsing symmetric motor and sensory dysfunction. Unlike its acute counterpart, Guillain-Barré syndrome (GBS), CIDP persists beyond 8 weeks, often leading to chronic disability if untreated. The estimated prevalence ranges from 1 to 9 cases per 100,000 individuals, with a slight male predominance.
Fig.1 Variants of CIDP: clinical and electrophysiological hallmarks of CIDP subtypes. (Lehmann H C, et al., 2019)
Pathogenesis of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
The pathogenesis of chronic inflammatory demyelinating polyneuropathy (CIDP) primarily involves autoimmune-mediated damage to peripheral nerve myelin, driven by both humoral and cellular immune mechanisms. Key factors include autoantibodies targeting nodal/paranodal proteins, T-cell infiltration releasing pro-inflammatory cytokines, and complement system activation leading to membrane attack complex (MAC)-mediated demyelination. Schwann cell dysfunction further impairs remyelination, while genetic predispositions and environmental triggers may initiate the immune response.
Fig.2 Pathogenesis of chronic inflammatory demyelinating polyneuropathy (CIDP) and potential targets of disease-modifying treatments (DMTs). (Kohle F, et al., 2023)
Therapeutic Development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
| Drug Names | Mechanism of Action | Targets | NCT Number | Research Phase |
| Empasiprubart | Complement C1s inhibitor (blocks classical complement pathway) | Complement C1s protease | NCT06920004 | Phase III |
| IMVT-1402 | Anti-FcRn monoclonal antibody (reduces pathogenic IgG levels) | Neonatal Fc receptor (FcRn) | NCT07032662 | Phase IIb |
| NVG-2089 | Selective immunomodulator (exact mechanism undisclosed) | Undisclosed | NCT07027111 | Phase II |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Our Services
As a preclinical research service provider for chronic inflammatory demyelinating polyneuropathy (CIDP), Protheragen provides end-to-end diagnostic and therapeutic development solutions. We excel in building physiologically relevant models, including in vitro models, animal models, and specialized blood-brain barrier (BBB) models, to enable comprehensive biomarker discovery, target validation, and CNS drug efficacy optimization.
Therapeutic Development Services
By Mechanism of Action
Disease Model Development Services
| Model Types | Model Names | |
|---|---|---|
| In Vitro Models | ||
| Microfluidic Models | ||
| Animal Models |
|
|
Protheragen is steadfastly dedicated to meticulously validating and optimizing therapies for chronic inflammatory demyelinating polyneuropathy (CIDP) through a thorough series of pharmacodynamics (PD), pharmacokinetics (PK) and toxicology studies. If you are interested in our services, please feel free to contact usfor more details and quotation information of related services.
References
- Lehmann H C, Burke D, Kuwabara S. Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment[J]. Journal of Neurology, Neurosurgery & Psychiatry, 2019, 90(9): 981-987.
- Kohle F, Dalakas M C, Lehmann H C. Repurposing MS immunotherapies for CIDP and other autoimmune neuropathies: unfulfilled promise or efficient strategy?[J]. Therapeutic Advances in Neurological Disorders, 2023, 16: 17562864221137129.